| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Activation of PPARalpha and PPARgamma by environmental phthalate monoesters.
|
Toxicol Sci
|
2003
|
2.20
|
|
2
|
Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis.
|
Mol Endocrinol
|
2006
|
2.17
|
|
3
|
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
|
Mol Cancer Ther
|
2008
|
1.96
|
|
4
|
MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets.
|
Genome Biol
|
2012
|
1.88
|
|
5
|
Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice.
|
Mol Endocrinol
|
2004
|
1.46
|
|
6
|
Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure associated with sex-specific liver gene expression.
|
Mol Cell Biol
|
2010
|
1.45
|
|
7
|
Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus.
|
Endocrinology
|
2007
|
1.39
|
|
8
|
Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver.
|
Mol Cell Biol
|
2011
|
1.36
|
|
9
|
Liver-specific hepatocyte nuclear factor-4alpha deficiency: greater impact on gene expression in male than in female mouse liver.
|
Mol Endocrinol
|
2008
|
1.30
|
|
10
|
Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic Acid microarray analysis.
|
Mol Endocrinol
|
2003
|
1.30
|
|
11
|
Codependence of growth hormone-responsive, sexually dimorphic hepatic gene expression on signal transducer and activator of transcription 5b and hepatic nuclear factor 4alpha.
|
Mol Endocrinol
|
2005
|
1.29
|
|
12
|
Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450.
|
Growth Factors
|
2004
|
1.29
|
|
13
|
Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis.
|
Physiol Genomics
|
2007
|
1.20
|
|
14
|
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
|
Mol Cancer Ther
|
2008
|
1.19
|
|
15
|
Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5.
|
Mol Endocrinol
|
2009
|
1.12
|
|
16
|
The structural basis of pregnane X receptor binding promiscuity.
|
Biochemistry
|
2009
|
1.09
|
|
17
|
Dynamic in vivo binding of STAT5 to growth hormone-regulated genes in intact rat liver. Sex-specific binding at low- but not high-affinity STAT5 sites.
|
Mol Endocrinol
|
2009
|
1.09
|
|
18
|
Sex-specific early growth hormone response genes in rat liver.
|
Mol Endocrinol
|
2008
|
1.08
|
|
19
|
Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b.
|
Toxicol Appl Pharmacol
|
2004
|
1.08
|
|
20
|
Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide.
|
J Biol Chem
|
2005
|
1.06
|
|
21
|
Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR).
|
Drug Metab Rev
|
2006
|
1.06
|
|
22
|
Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice.
|
J Pharmacol Exp Ther
|
2005
|
1.06
|
|
23
|
Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease.
|
PLoS One
|
2011
|
1.06
|
|
24
|
Intrinsic sex differences in the early growth hormone responsiveness of sex-specific genes in mouse liver.
|
Mol Endocrinol
|
2010
|
1.05
|
|
25
|
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
|
Mol Cancer Ther
|
2006
|
1.05
|
|
26
|
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
|
Cancer Res
|
2012
|
1.05
|
|
27
|
Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
|
Mol Pharmacol
|
2004
|
1.04
|
|
28
|
Characterization of three growth hormone-responsive transcription factors preferentially expressed in adult female liver.
|
Endocrinology
|
2007
|
1.03
|
|
29
|
Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver.
|
Mol Cell Biol
|
2013
|
1.03
|
|
30
|
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
|
Biochemistry
|
2005
|
1.02
|
|
31
|
Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.
|
Clin Cancer Res
|
2009
|
1.01
|
|
32
|
Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization.
|
J Biol Chem
|
2005
|
1.01
|
|
33
|
trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals.
|
Toxicol Sci
|
2004
|
1.00
|
|
34
|
A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
|
J Pharmacol Exp Ther
|
2007
|
0.99
|
|
35
|
Sex-specific mouse liver gene expression: genome-wide analysis of developmental changes from pre-pubertal period to young adulthood.
|
Biol Sex Differ
|
2012
|
0.98
|
|
36
|
Conditionally replicating adenoviruses for cancer treatment.
|
Curr Cancer Drug Targets
|
2007
|
0.98
|
|
37
|
Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.
|
Mol Cancer Ther
|
2007
|
0.97
|
|
38
|
PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis.
|
Mol Cancer
|
2010
|
0.97
|
|
39
|
Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy.
|
Cancer Res
|
2004
|
0.96
|
|
40
|
Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methylcholanthrene.
|
Toxicol Appl Pharmacol
|
2005
|
0.96
|
|
41
|
Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).
|
Carcinogenesis
|
2006
|
0.95
|
|
42
|
Antiangiogenesis enhances intratumoral drug retention.
|
Cancer Res
|
2011
|
0.95
|
|
43
|
Role of hepatocyte nuclear factors in transcriptional regulation of male-specific CYP2A2.
|
J Biol Chem
|
2004
|
0.93
|
|
44
|
Interactions of methoxyacetic acid with androgen receptor.
|
Toxicol Appl Pharmacol
|
2008
|
0.93
|
|
45
|
Environmental phthalate monoesters activate pregnane X receptor-mediated transcription.
|
Toxicol Appl Pharmacol
|
2004
|
0.92
|
|
46
|
Impact of CUX2 on the female mouse liver transcriptome: activation of female-biased genes and repression of male-biased genes.
|
Mol Cell Biol
|
2012
|
0.91
|
|
47
|
Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b.
|
Biochem J
|
2006
|
0.90
|
|
48
|
Environmental and endogenous peroxisome proliferator-activated receptor gamma agonists induce bone marrow B cell growth arrest and apoptosis: interactions between mono(2-ethylhexyl)phthalate, 9-cis-retinoic acid, and 15-deoxy-Delta12,14-prostaglandin J2.
|
J Immunol
|
2004
|
0.90
|
|
49
|
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
|
Toxicol In Vitro
|
2005
|
0.90
|
|
50
|
Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
|
Drug Metab Dispos
|
2005
|
0.90
|
|
51
|
Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma.
|
Mol Pharmacol
|
2003
|
0.89
|
|
52
|
Sexual dimorphism of rat liver nuclear proteins: regulatory role of growth hormone.
|
Mol Cell Proteomics
|
2004
|
0.88
|
|
53
|
Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
|
Cancer Gene Ther
|
2003
|
0.87
|
|
54
|
Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide.
|
Arch Biochem Biophys
|
2007
|
0.87
|
|
55
|
Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.
|
Hum Gene Ther
|
2008
|
0.87
|
|
56
|
Cancer chemotherapy and drug metabolism.
|
Drug Metab Dispos
|
2005
|
0.87
|
|
57
|
Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation.
|
Methods Mol Biol
|
2006
|
0.86
|
|
58
|
Computational screening of phthalate monoesters for binding to PPARgamma.
|
Chem Res Toxicol
|
2006
|
0.85
|
|
59
|
Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes.
|
Arch Biochem Biophys
|
2004
|
0.85
|
|
60
|
Computational solvent mapping reveals the importance of local conformational changes for broad substrate specificity in mammalian cytochromes P450.
|
Biochemistry
|
2006
|
0.85
|
|
61
|
Toxicity of ethylene glycol monomethyl ether: impact on testicular gene expression.
|
Int J Androl
|
2007
|
0.84
|
|
62
|
Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
|
Curr Pharm Des
|
2002
|
0.84
|
|
63
|
Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
|
Cancer Lett
|
2012
|
0.83
|
|
64
|
Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone.
|
Drug Metab Dispos
|
2009
|
0.83
|
|
65
|
Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.
|
Drug Metab Dispos
|
2010
|
0.82
|
|
66
|
Complex modulation of androgen responsive gene expression by methoxyacetic acid.
|
Reprod Biol Endocrinol
|
2011
|
0.82
|
|
67
|
The induction of atherogenic dyslipidaemia in poloxamer 407-treated mice is not mediated through PPARalpha.
|
J Pharm Pharmacol
|
2008
|
0.82
|
|
68
|
Impact of methoxyacetic acid on mouse Leydig cell gene expression.
|
Reprod Biol Endocrinol
|
2010
|
0.82
|
|
69
|
Wavelength-dependent backscattering measurements for quantitative monitoring of apoptosis, part 1: early and late spectral changes are indicative of the presence of apoptosis in cell cultures.
|
J Biomed Opt
|
2011
|
0.82
|
|
70
|
Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
|
Cancer Res
|
2002
|
0.81
|
|
71
|
DNase I digestion of isolated nulcei for genome-wide mapping of DNase hypersensitivity sites in chromatin.
|
Methods Mol Biol
|
2013
|
0.81
|
|
72
|
Wavelength-dependent backscattering measurements for quantitative monitoring of apoptosis, part 2: early spectral changes during apoptosis are linked to apoptotic volume decrease.
|
J Biomed Opt
|
2011
|
0.81
|
|
73
|
Pregnane X receptor-mediated transcription.
|
Methods Enzymol
|
2005
|
0.81
|
|
74
|
Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
|
Mol Pharmacol
|
2004
|
0.81
|
|
75
|
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
|
Mol Cancer Ther
|
2013
|
0.80
|
|
76
|
Elevated basal expression of liver peroxisomal beta-oxidation enzymes and CYP4A microsomal fatty acid omega-hydroxylase in STAT5b(-/-) mice: cross-talk in vivo between peroxisome proliferator-activated receptor and signal transducer and activator of transcription signaling pathways.
|
Toxicol Appl Pharmacol
|
2002
|
0.80
|
|
77
|
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
|
J Pharmacol Exp Ther
|
2012
|
0.79
|
|
78
|
Changes in mouse uterine transcriptome in estrus and proestrus.
|
Biol Reprod
|
2013
|
0.79
|
|
79
|
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
|
Arch Biochem Biophys
|
2003
|
0.79
|
|
80
|
Cytochrome-P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity in glomerular epithelial cells.
|
Kidney Int
|
2010
|
0.79
|
|
81
|
Evaluation of thyroid hormone effects on liver P450 reductase translation.
|
Arch Biochem Biophys
|
2003
|
0.77
|
|
82
|
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
|
BMC Cancer
|
2010
|
0.77
|
|
83
|
Isolation of nuclei for use in genome-wide DNase hypersensitivity assays to probe chromatin structure.
|
Methods Mol Biol
|
2013
|
0.77
|
|
84
|
Determination of CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes.
|
Methods Mol Biol
|
2006
|
0.77
|
|
85
|
Post-transcriptional regulation of hepatic NADPH-cytochrome P450 reductase by thyroid hormone: independent effects on poly(A) tail length and mRNA stability.
|
Mol Pharmacol
|
2002
|
0.76
|
|
86
|
CYP2D6-dependent bufuralol 1'-hydroxylation assayed by reverse-phase ion-pair high-performance liquid chromatography with fluorescence detection.
|
Methods Mol Biol
|
2006
|
0.76
|
|
87
|
Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate.
|
Methods Mol Biol
|
2006
|
0.76
|
|
88
|
Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high-performance liquid chromatography with radiometric detection.
|
Methods Mol Biol
|
2006
|
0.76
|
|
89
|
Determination of CYP2C9-catalyzed diclofenac 4'-hydroxylation by high-performance liquid chromatography.
|
Methods Mol Biol
|
2006
|
0.76
|
|
90
|
Cytochrome p450-based gene therapies for cancer.
|
Methods Mol Med
|
2004
|
0.75
|
|
91
|
Circulating free fatty acids are increased independently of PPARgamma activity after administration of poloxamer 407 to mice.
|
Can J Physiol Pharmacol
|
2008
|
0.75
|
|
92
|
Correction: Chemical and Hormonal Effects on STAT5b- Dependent Sexual Dimorphism of the Liver Transcriptome.
|
PLoS One
|
2016
|
0.75
|
|
93
|
Cytochrome P450 2B1 mediates complement-dependent sublytic injury in a model of membranous nephropathy.
|
J Biol Chem
|
2010
|
0.75
|
|
94
|
CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection.
|
Methods Mol Biol
|
2006
|
0.75
|
|
95
|
High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation.
|
Methods Mol Biol
|
2006
|
0.75
|
|
96
|
Catalytic assays for human cytochrome P450: an introduction.
|
Methods Mol Biol
|
2006
|
0.75
|